Cholesterol management in patients with heart disease: Emphasizing secondary prevention to increase longevity

Postgraduate Medicine

Volumn 102, Issue 2, 1997, Pages 81-90

  Grundy, Scott M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLESTIPOL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PREVALITE; SIMVASTATIN; UNCLASSIFIED DRUG;

DIET THERAPY; GASTROINTESTINAL TOXICITY; GLUCOSE INTOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERURICEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MYOPATHY; REVIEW; SKIN TOXICITY;

EID: 0030814081     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1997.08.292     Document Type: Review

References (13)

1. Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Ann Intern Med 1990; 112(10):780-92
2. Sempos C, Cooper R, Kovar MG, et al. Divergence of the recent trends in coronary mortality for the four major race-sex groups in the United States. Am J Public Health 1988;78(11): 1422-7
3. Smith SC Jr, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Circulation 1995;92(1):2-4
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89(3):1333-445
5. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990; 323(16):1112-9
6. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed) 1988;296(6618): 320-31
7. Brown BG, Zhao XQ, SaccoDE, et al. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87(6):1781-91
8. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69(5):377-81
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-9
10. Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335(14): 1001-9
11. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92(9):2419-25
12. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. 1995 Sep 14-5. J Am Coll Cardiol 1996; 27(5):957-1047
13. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93(10):1796-802